Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

October 30, 2020 8:00 AM

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970s VANCOUVER, BC / ACCESSWIRE / October 30, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive...

Read more

Helix BioPharma Corp. Announced Fiscal 2020 Year-End Results

October 29, 2020 5:50 PM

RICHMOND HILL, ON / ACCESSWIRE / October 29, 2020 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its financial results for the 2020 fiscal year ended July 31, 2020. OVERVIEW The Company reported a consolidated net loss and total...

Read more

Apollo Endosurgery, Inc. to Report Third Quarter 2020 Results on November 5, 2020

October 29, 2020 4:40 PM

AUSTIN, TX / ACCESSWIRE / October 29, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020, after the U.S. stock markets close. Apollo will hold a conference call on Thursday,...

Read more

Dyadic to Report Third Quarter 2020 Financial Results on Thursday, November 12, 2020

October 29, 2020 4:30 PM

JUPITER, FL / ACCESSWIRE / October 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended September 30, 2020...

Read more

Wuhan General Group Updates on University of Pretoria Research Collaboration for Psilocybin Magic Mushroom Clinical Trials

October 29, 2020 11:10 AM

CAPE TOWN, SA / ACCESSWIRE / October 29, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The company's subsidiary MJ Medtech is pleased to announce it has formalized and executed a research collaboration and funding agreement with the...

Read more

Experion Reports Third Straight Quarter of Record Revenue Growth in Q3 and Reports on Financial and Operational Highlights

October 29, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / October 29, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), a cultivator and processor of premium cannabis products, is pleased to announce its financial results for its third quarter and for the period ended August 31, 2020. Jarrett Malnarich, CEO of Experion, stated, "This is our third consecutive quarter of sequential sales growth,...

Read more

Interim Management Statement Q3 2020 of Molecular Partners: Emergence of New Opportunities and Strong Platform Validation of DARPin® Therapeutics

October 29, 2020 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 29, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending September30, 2020. "Responding to the global COVID-19 pandemic requires an unprecedented effort on the part of therapeutics innovators like...

Read more

Applied UV, Inc. Announces Exclusive Licensing and Joint Development Agreement with Axis Lighting to Commercialize LED-based Technologies in UV-C Devices to Inactivate Pathogens on Surfaces in the Hospital Market

October 28, 2020 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / October 28, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, today announced that its subsidiary, SteriLumen, Inc. ("SteriLumen"), and Axis Lighting, Inc. of Quebec,...

Read more

Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery

October 28, 2020 8:30 AM

First CoreoGraft Recipient Discharged from the Hospital IRVINE, CA / ACCESSWIRE / October 28, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the first heart bypass surgery in HJLI's first-in-human CoreoGraft study was successfully completed and the patient has been discharged from the hospital. The protocol for the first-in-human study...

Read more

Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020

October 28, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate...

Read more

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

October 28, 2020 2:15 AM

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage Molecular...

Read more

Hancock Jaffe Submits VenoValve Pre-IDE Filing to FDA

October 27, 2020 8:30 AM

Requests Pre-IDE Meeting with FDA IRVINE, CA / ACCESSWIRE / October 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a Pre-IDE filing to the U.S. Food and Drug Administration ("FDA") and has requested a meeting with the FDA to discuss a few key matters in advance of the filing of its IDE application for the...

Read more

Lexaria Bioscience Extends Warrant Term

October 26, 2020 2:30 PM

KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the "Warrants"), which were issued pursuant to a private placement of units. The Warrants were issued in two tranches pursuant to which 1,554,245 Warrants...

Read more

Medspresso Launches Handcrafted Delights, CBD Infused Functional Foods

October 26, 2020 10:10 AM

CAPE TOWN, SA / ACCESSWIRE / October 26, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update regarding its Medspresso brand: The company is pleased to announce the upcoming product launch of "Handcrafted Delights" by MedspressoTM. The new line...

Read more

Experion Holdings Ltd. Hires New Chief Financial Officer

October 26, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / October 26, 2020 / The Board of Directors of Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) and CEO Mr. Jarrett Malnarich are pleased to announce the appointment of Mr. Kerry Biggs to the position of Chief Financial Officer commencing October 23 2020, replacing Interim CFO, Mr. Sean McNeil, who remains Chairman of the Board of Experion. "We...

Read more

Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19

October 22, 2020 6:30 AM

Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID OTTAWA, ON / ACCESSWIRE / October 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in...

Read more

Hancock Jaffe Announces One Year Follow-up Data on Ninth VenoValve Patient

October 21, 2020 12:15 PM

Patient Continues to Show Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / October 21, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the ninth VenoValve patient in HJLI's first-in-human, clinical study has successfully reached the one-year milestone. Patient 9's chronic venous insufficiency ("CVI") has...

Read more

BioLargo Awarded Contract for Engineering Services at Major Chemical Manufacturing Facility

October 21, 2020 9:00 AM

WESTMINSTER, CA / ACCESSWIRE / October 21, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US,...

Read more

Hillstream BioPharma Completes Pre-IND Review with FDA on HSB-1216 for Small Cell Lung Cancer (SCLC)

October 21, 2020 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / October 21, 2020 / Hillstream BioPharma Inc. ("Hillstream", the "Company"), a clinical-stage pharmaceutical company, announced that it has successfully completed a pre-Investigational New Drug (IND) review citing a written response from the U.S. Food and Drug Administration (FDA). The pre-IND review focused on the development plan for Hillstream's HSB-1216, including the clinical study...

Read more

Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx

October 21, 2020 7:00 AM

Tetra will leverage its recent Dronabinol data pack acquisition to rapidly file its second New Drug Submission application to commercialize another THC-based prescription drug Further reinforces its patent protection and life cycle management on its dronabinol franchise Shown in a clinical trial to have fewer side effects and enhanced bioavailability Solidifies Tetra's revenue stream OTTAWA, ON / ACCESSWIRE / October 21,...

Read more